Contract research organization Inotiv announced a partnership with Vugene to integrate the Lithuanian firm’s multiomics AI platform into early discovery workflows, aiming to improve efficacy and safety predictions. Company statements quote Inotiv leadership saying the collaboration will enhance translational decision‑making in client programs. Under the deal, Inotiv will apply Vugene’s platform — which analyzes genomics, transcriptomics, proteomics, metabolomics and epigenomics — to identify biomarkers and prioritize targets. The partnership is representative of increasing CRO demand for AI‑driven bioinformatics to shorten lead identification timelines and de‑risk preclinical hypotheses. Clarifier: multiomics integrates multiple molecular data types to generate more holistic models of disease biology and drug response, improving translational relevance compared with single‑omics approaches.